LyGenesis Announces First Patient Dosed in its Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease

Good news!

""In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," ... "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients." ..."

LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease | Lygenesis

‘Mini liver’ will grow in person’s own lymph node in bold new trial Biotechnology firm LyGenesis has injected donor cells into a person with liver failure for the first time.

Credits: Human Progress Weekly Progress Roundup

Researchers injected a mouse’s lymph node with liver cells (green), converting the organ into a ‘mini liver’.